头孢丙烯治疗急性细菌性下呼吸道感染的临床疗效评价

目的 :评价头孢丙烯治疗急性细菌性下呼吸道感染的临床有效性、安全性。方法 :轻、中度急性细菌性下呼吸道感染病人 115例随机分成 2组 ,头孢丙烯组 5 8例 (男性 37例 ,女性 2 1例 ;年龄 4 7a±s 13a)予头孢丙烯 5 0 0mg ,po ,bid ;头孢克洛组5 7例 (男性 34例 ,女性 2 3例 ;年龄 4 9a± 12a)予头孢克洛 5 0 0mg ,po ,tid。 2组均以 7～ 14d为一个疗程。结果 :头孢丙烯组与头孢克洛组的临床有效率分别为 93%与 91% (P >0 .0 5 ) ,细菌清除率为92 %与 89% (P >0 .0 5 ) ,2组均无明显不良反应。结论 :头孢丙烯可作为治疗轻、中度急性细菌性下呼吸道感染有效和安全的抗生素

Evaluation of clinical effect of cefprozil in treating acute bacterial lower respiratory tract infections

AIM:To evaluate the clinical efficacy, safety of cefprozil in treating acute bacterial lower respiratory tract infection. METHODS: One hundred and fifteen patients with mild to moderate acute bacterial lower respiratory tract infection were divided into two groups. Fifty-eight patients (M 37,F 21;age 47 a± s13 a) were treated with cefprozil 500 mg,po,bid, Fifty-seven patients (M 34,F 23;age 49 a± 12 a) were treated with cefaclor 500 mg,po,tid. In both groups were 7-14 d were as a treatment course. RESULTS: The total clinical effective rates of cefprozil and cefaclor were 93 % and 91 %(P>0.05),respectively. The bacterial clearance rates were 92 % and 89 %(P>0.05), respectively.Both groups were without obvious adverse reactions. CONCLUSION: Cefprozil is a safe and potent antibacterial agent in treating mild to moderate acute bacterial lower respiratory tract infections.